These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 15901204

  • 1. Statins and the response to myocardial injury.
    Scalia R.
    Am J Cardiovasc Drugs; 2005; 5(3):163-70. PubMed ID: 15901204
    [Abstract] [Full Text] [Related]

  • 2. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
    Bulhak A, Roy J, Hedin U, Sjöquist PO, Pernow J.
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
    Weinberg EO, Scherrer-Crosbie M, Picard MH, Nasseri BA, MacGillivray C, Gannon J, Lian Q, Bloch KD, Lee RT.
    Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1802-9. PubMed ID: 15563531
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
    Nusca A, Melfi R, Patti G, Sciascio GD.
    Future Cardiol; 2010 Sep; 6(5):579-89. PubMed ID: 20932108
    [Abstract] [Full Text] [Related]

  • 12. Effects of rosuvastatin on ADMA, rhokinase, NADPH oxidase, caveolin-1, hsp 90 and NFkB levels in a rat model of myocardial ischaemia-reperfusion.
    Burma O, Onat E, Uysal A, Ilhan N, Erol D, Ozcan M, Sahna E.
    Cardiovasc J Afr; 2014 Sep; 25(5):212-6. PubMed ID: 25629537
    [Abstract] [Full Text] [Related]

  • 13. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.
    Vilahur G, Casaní L, Peña E, Duran X, Juan-Babot O, Badimon L.
    Atherosclerosis; 2009 Sep; 206(1):95-101. PubMed ID: 19419716
    [Abstract] [Full Text] [Related]

  • 14. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 15. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
    Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R.
    Cardiovasc Res; 2005 Jun 01; 66(3):462-71. PubMed ID: 15914111
    [Abstract] [Full Text] [Related]

  • 16. Short-term statin treatment does not prevent ischemia and reperfusion-induced endothelial dysfunction in humans.
    Wouters CW, Wever KE, Bronckers I, Hopman MT, Smits P, Thijssen DH, Rongen GA.
    J Cardiovasc Pharmacol; 2012 Jan 01; 59(1):22-8. PubMed ID: 21885990
    [Abstract] [Full Text] [Related]

  • 17. Rosuvastatin calcium in acute coronary syndromes.
    Aggarwal RK, Showkathali R.
    Expert Opin Pharmacother; 2013 Jun 01; 14(9):1215-27. PubMed ID: 23574635
    [Abstract] [Full Text] [Related]

  • 18. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group.
    Circ Cardiovasc Qual Outcomes; 2009 Nov 01; 2(6):616-23. PubMed ID: 20031900
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G, Maggioni AP.
    Adv Ther; 2009 May 01; 26(5):469-87. PubMed ID: 19444394
    [Abstract] [Full Text] [Related]

  • 20. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
    Bulhak AA, Gourine AV, Gonon AT, Sjöquist PO, Valen G, Pernow J.
    Acta Physiol Scand; 2005 Feb 01; 183(2):151-9. PubMed ID: 15676056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.